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Tuberculosis remains a major cause of morbidity and mortality
globally, with an estimated nine million people developing the
disease and 1.5 million deaths in 2013; equating to 4100 deaths
a day.1 Nevertheless, considerable gains have been made in
international tuberculosis control; incidence rates are decreasing
(albeit slowly) and mortality has been reduced by 45%
worldwide. The advent of multidrug resistant tuberculosis
threatens this progress. In this review we detail the challenges
faced globally in the diagnosis, treatment, and control of
multidrug resistant tuberculosis and why this matters to high
and low burden multidrug resistant tuberculosis settings alike.
What is multidrug resistant tuberculosis?
Rifampicin and isoniazid form the backbone of conventional
first line treatment for tuberculosis. Multidrug resistant
tuberculosis refers to tuberculosis that is resistant to both
rifampicin and isoniazid. This classification is important because
treatment outcomes for this group of patients are far worse than
for patients with fully drug susceptible or lesser forms of drug
resistant tuberculosis.1 2 Multidrug resistant tuberculosis with
additional resistance to any fluoroquinolone (such as ofloxacin
or moxifloxacin) and also any one of the three second line
injectable agents (amikacin, capreomycin, kanamycin) is
designated as extensively drug resistant tuberculosis.
How common is it?
“Missing” patients are a major problem in assessing the burden
of tuberculosis globally.1 Without access to universal drug
susceptibility testing, national tuberculosis programmes have
to estimate burden by extrapolation from periodic national or
subnational surveys. This generates the global estimate of 480
000 cases of multidrug resistant tuberculosis in 2013 (range 350
000-610 000), of which 9% have extensively drug resistant
tuberculosis. Out of the estimated 480 000 cases of multidrug
resistant tuberculosis in 2013, only 136 000 were reported to
the World Health Organization.1 Globally, the main barrier to
diagnosis is the lack of access to drug susceptibility testing in
quality assured laboratories. Even among bacteriologically
confirmed cases of tuberculosis, few were tested for multidrug
resistant tuberculosis, with particularly low levels in the African
and South East Asia regions.1 In the United Kingdom, where
all patients with tuberculosis undergo drug susceptibility testing
and ascertainment is therefore believed to be almost complete,
the reported number of cases remains small but increased from
28 to 81 per year from 2000 to 2012.3
What is the prognosis?
An estimated 210 000 deaths (range 130 000-290 000) occur
from multidrug resistant tuberculosis worldwide each year, as
a consequence of never being diagnosed, the gap between
diagnosis and treatment, and poor treatment outcomes.
Worldwide, fewer than half of cases achieve treatment success.1
In the United Kingdom more than 70% of patients with
multidrug resistant tuberculosis achieve treatment success, but
it has been shown that it is possible to achieve comparable (or
even better) outcomes, even in low income settings.4
Who is at risk of multidrug resistant
tuberculosis?
All patients with tuberculosis should undergo drug susceptibility
testing because only testing those perceived to be at risk will
miss up to half of multidrug resistant cases.1 Nevertheless, it is
clear that multidrug resistant tuberculosis is more common in
some groups, such as the former prison inmate in the example
(box 1). In all settings patients who have previously been treated
for tuberculosis are at higher risk for multidrug resistant
tuberculosis, with recent estimates suggesting that 3.5% of new
cases and 20.5% of previously treated cases have multidrug
resistant tuberculosis.1 However, rates of multidrug resistant
tuberculosis vary considerably between countries and regions
(table⇓) with 27 high burden countries accounting for more than
85% of cases. Worldwide, China, India, and the Russian
Federation contribute the largest total number of cases. However,
the highest proportions are found in eastern Europe and Central
Asia, with around 20% of new cases and 50% of previously
treated cases havingmultidrug resistant tuberculosis. In countries
with a high burden of tuberculosis such as South Africa, even
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The bottom line
Multidrug resistant tuberculosis refers to tuberculosis with resistance to at least rifampicin and isoniazid
Multidrug resistant tuberculosis is increasingly common; however, there is a large shortfall between the estimated total number of cases
and the numbers diagnosed and treated
Diagnosis is hampered by lack of access to quality assured diagnostics, although newer, rapid molecular and phenotypic methods may
go some way to improving this situation
Compared with drug susceptible tuberculosis, treatment for multidrug resistant tuberculosis requires the use of drug regimens that are
prolonged (18-24 months), less efficacious, and noticeably more toxic; new drugs and regimens are becoming available for the first time
in decades and ongoing trials should define how best they should be used
Worldwide, treatment success is only around 50%; however, several settings, including some low income countries, have proved that
higher success rates are achievable
Sources and selection criteria
We searched Medline, Embase, and Scielo with the terms “MDR TB”, “Tuberculosis, Multidrug-Resistant”. We also reviewed the World
Health Organization Global Tuberculosis Report 2014 and other national tuberculosis programme reports. We included data from systematic
reviews/meta-analyses, randomised controlled trials, and good quality observational studies focused on multidrug resistant tuberculosis.
a relatively low percentage of multidrug resistant tuberculosis
among the large number of cases translates into a high incidence
rate when expressed as cases of multidrug resistant tuberculosis
per 100 000 population per year.
In the United Kingdom 1.4% of new and 5.7% of previously
treated patients have multidrug resistant tuberculosis, with 89%
of these patients being born outside the United Kingdom (45%
from South Asia, 19% from eastern Europe and 19% from
Sub-Saharan Africa).5 The proportion of multidrug resistant
tuberculosis in UK cases of tuberculosis in 2013 did not exceed
6% in most groups. Strikingly, however, for people born in
eastern Europe it was over 24%.4
Once drug resistance develops the possibility of transmission
to other people emerges, with up to half of multidrug resistant
tuberculosis cases arising in this way.1 3 6 7 In addition, in high
incidence settings where reinfection is common, an unknown
fraction of previously treated people with tuberculosis will have
been infected by multidrug resistant tuberculosis unrelated to
their previous infection and thus transmission rates are likely
to be systematically underestimated. Other risk factors for
multidrug resistant tuberculosis may include being a household
contact of a known infected person, younger age, and
(putatively) the strain type of tuberculosis.8 9
How is it diagnosed?
The diagnosis of multidrug resistant tuberculosis is based on
the detection of resistance to rifampicin and isoniazid in the
causative organism in a clinical sample, usually sputum. The
quality and quantity of the sputum sample can affect test
performance.10An increasing array of new tools for the diagnosis
of multidrug resistance has become available in recent years,
for the detection of either phenotypic (growth based) or
genotypic (molecular markers) resistance. The use of specific
tests in different regions is heterogeneous and most regions will
use several different tests in combination.
Phenotypic indirect drug susceptibility testing
Conventional phenotypic tests use methods of indirect drug
susceptibility testing. This requires an isolate to be cultured first
and then inoculated into solid or liquid media. This leads to a
considerable delay until results are available, often several
months, therefore results are often not available in a clinically
useful timeframe. Automated systems such as theMycobacteria
Growth Indicator Tube 960 (MGIT 960, Becton Dickinson
Microbiology Systems, Sparks, MD) speed up culture times
through the use of liquid media and automated sensing of culture
positivity, but still require subsequent indirect sensitivity testing.
High throughput is a major advantage although tempered by
relatively high cost and contamination rates.
Phenotypic direct drug susceptibility testing
Phenotypic direct drug susceptibility testing delivers a result
direct from inoculation of the sputum sample thus does not need
to be subcultured. Samples are inoculated into media containing
drugs at specific critical concentrations such that the presence
of growth (whether detected by a colour change or visual
identification of microscopic growth) is indicative of phenotypic
resistance.11 12 These methods are rapid, non-commercial, and
low cost making them well suited to resource constrained
settings with a high burden of tuberculosis.13 Tests endorsed by
WHO include microscopic observation drug susceptibility
(MODS) and the nitrate reductase assay.
Genotypic drug susceptibility testing
Genotypic methods test for the presence of known resistance
mutations associated with multidrug resistant tuberculosis. Two
types of geneotypic assay have been endorsed by WHO:
molecular beacon assays and line probe hybridisation assays.
WHO has endorsed the use of the molecular beacon assay Xpert
MTB/RIF (Cepheid, Sunnyvale, CA) as an initial diagnostic
test where multidrug resistant tuberculosis is common.14 This
test is a real time polymerase chain reaction that detects
Mycobacterium tuberculosis and rifampicin resistance (by
identification of mutations in the mycobacterial rpoB gene). It
is performed directly on sputum, with a turnaround time of two
hours, which is a key advantage. Identification of resistance to
rifampicin still necessitates subsequent andmore extensive drug
susceptibility testing of other first line and second line agents,
usually by phenotypic (culture based) methods. There are
concerns about false negative and false positives test results for
rifampicin resistance15 and the increased frequency of mixed
infections in high prevalence settings,16 so local evaluation of
multidrug resistant tuberculosis epidemiology before rollout
may be prudent. The higher cost of the test compared with
phenotypic testing is also a constraint, particularly since
isoniazid susceptibility testing is not assessed. Costs range from
$10 (£6; €9) (for low income countries) for each test, to more
than $70.17 18
An alternative molecular test platform endorsed byWHO is the
line probe assay.19 This assay exists in two main commercial
forms—the INNO-LipA Rif.TB (Fujirebio Europe, Ghent,
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Box 1 An example of how multidrug resistant tuberculosis might present
A 40 year old man, originally from the Russian Federation and now resident in London, presented to the emergency department of his local
hospital with a history of dry cough, fever, and night sweats for several months. His medical history was unremarkable and he had never
previously received treatment for tuberculosis. He had spent two years in a Russian prison three years previously. His chest radiograph
revealed patchy shadowing in the right upper lobe with several cavities. Sputum was positive for acid fast bacilli and he was prescribed
standard first line quadruple tuberculosis treatment as an outpatient, with a combination of rifampicin and isoniazid, pyrazinamide, and
ethambutol. Despite this, his symptoms remained and five weeks later the results of a sputum culture confirmedMycobacterium tuberculosis
with resistance to rifampicin and isoniazid.
Belgium), which detects rifampicin resistance, and Genotype
MTBDRplus (Hain Lifescience, Nehren, Germany), which
identifies rifampicin (through detection of mutations in the rpoB
gene) and isoniazid resistance (mutations in the katG and inhA
genes).20 It is performed on cultured isolates or on smear positive
sputum samples,21 and a version is now available (genotype
MTBDRsl), although not yet endorsed by WHO, for
fluoroquinolone, aminoglycoside, and ethambutol drug
susceptibility testing.22
As whole genome sequencing becomes increasingly affordable
and accessible, the horizon holds potential promise of a single
technology that could be utilised simultaneously to detect
genotypic resistance to rifampicin and isoniazid and key second
line drugs—although somework is needed to characterise a full
library of resistance conferring mutations. A useful byproduct
of sequencing in this way would be the molecular
epidemiological insights yielded into the contribution of
transmission (as opposed to reactivation of latent multidrug
resistant tuberculosis infection) in different settings.23
How is it treated?
Of the 136 000 patients with multidrug resistant tuberculosis
reported in 2013, just over 71% (97 000) began treatment.1 This
treatment gap is heterogeneous between countries, with fewer
than half of eligible patients enrolled in treatment in the African
region. However, these numbers seem to represent progress,
particularly in India, Russia, and South Africa, with a more than
150% increase in enrolment to treatment since 2009.1Achieving
the goal of universal access to the diagnosis and treatment of
multidrug resistant tuberculosis requires the strengthening of
health services in general. Simply improving rates of treatment
initiation in a poor programme is likely to be ineffective and
may increase rates of drug resistance and promote transmission.24
Recommended drug regimens
Currently recommended treatment for multidrug resistant
tuberculosis requires 18-24 months of at least five drugs, none
of which are as potent as rifampicin or isoniazid and all of which
are more toxic and less well tolerated. Countries with access to
quality assured drug susceptibility testing for second line drugs
are likely to offer an “individualised” regimen tailored to a
patient’s resistance pattern. Countries without this facility are
likely to offer a “standardised” regimen, which is broadly similar
for all patients and based on historical resistance patterns and
which drugs have been used in that region. Even in the context
of individualised regimens, initial treatment is often empirical
(and based on similar principles to standardised treatment),
pending second line drug susceptibility testing.25
Multidrug resistant tuberculosis should be treated with an
injectable agent such as amikacin, kanamycin, or capreomycin
(streptomycin is usually not used because of high rates of
resistance), a fluoroquinolone (levofloxacin, moxifloxacin, or
gatifloxacin are recommended), and at least three other agents
with probable activity (ethionamide or prothionamide,
cycloserine, para-aminosalicylic acid). First line agents (that is,
pyrazindamide and ethambutol) with retained activity can also
be used.
Ideally the injectable agent is administered daily for the first
6-8 months, forming an “intensive phase” of treatment, with
the other drugs then continued, forming a “continuation phase.”25
In practice, adverse effects often supervene (see example in box
2) and require stopping the injectable agent, managing side
effects or swapping drugs for remaining alternatives.
Challenges to management
Managing the side effects of treatment forms an important part
of management and a failure to do so can affect adherence and
drive the development of further resistance. Particularly common
side effects include local injection site complications,
ototoxicity, and nephrotoxicity from the injectable agents;
neuropsychiatric symptoms and seizures with cycloserine; and
diarrhoea with para-aminosalicylate sodium. Hypothyroidism
can occur with ethionamide or prothionamide or
para-aminosalicylic acid. Drug induced hepatitis is not
uncommon, particularly in association with pyrazinamide.
Delivery and monitoring of the drug regimens is complex, and
drug stockouts are common and undermine efforts. All regimens
are based on cohort data and expert opinion, with a conspicuous
absence of randomised controlled trial evidence to inform
treatment. However, the available evidence does suggest better
outcomes for patients treated with a later generation quinolone,
ethionamide or prothionamide, four or more effective drugs in
the intensive phase, and three or more effective drugs in the
continuation phase.26 Extensively drug resistant tuberculosis
treatment is even more challenging and often relies on drugs
with only in vitro or animal data to support their use.
Emerging treatments
For the first time in over 40 years new antituberculosis drugs
are becoming available; notably delamanid and bedaquiline,
both of which already have a compassionate use role in difficult
to treat multidrug resistant tuberculosis and extensively drug
resistant tuberculosis. Furthermore there is renewed interest in
the efficacy of clofazamine and linezolid. However, an urgent
need remains for better regimens rather than new single drugs,
and for this reason a handful of phase III trials are in progress.
Promising results have been reported with the use of a nine
month regimen in Bangladesh and several West African
countries, which is now being formally tested in a randomised
controlled trial.27 One view is that some regimens under
investigation may ultimately be effective for all strains of
tuberculosis whether or not susceptible to rifampicin or
isoniazid, which would considerably attenuate the importance
of the notion of multidrug resistant tuberculosis in global
tuberculosis.
What is the role of palliative care?
Some patients with multidrug resistant tuberculosis will, despite
apparently adequate treatment, fail to respond and require
palliative care. This is particularly a problem for patients with
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Box 2 Example of how drug side effects can affect treatment
After the symptoms of a 26 year old Swazi woman failed to respond to two months of first line tuberculosis treatment (isoniazid, rifampicin,
ethambutol, pyrazinamide) she underwent drug susceptibility testing and was found to have multidrug resistant tuberculosis. Treatment was
started with moxifloxacin, kanamycin, ethionamide, and cycloserine, and she continued with pyrazinamide. Early substitution of cycloserine,
to which her unbearable initial low mood and irritability was attributed, with para-aminosalicylate sodium replaced neuropsychiatric side
effects with profuse diarrhoea. The onset of aminoglycoside induced hearing loss and the prospect of going deaf led to the patient discontinuing
treatment after completing only four of 18 months of the regimen.
extensively drug resistant tuberculosis. Moreover, there are
increasing reports of patients with no treatment options. Only
11 countries with a high burden of multidrug resistant
tuberculosis (South Africa the only one outside Europe) reported
palliative care facilities as part of their national tuberculosis
plan.1 In high burden countries such as South Africa, where
resources for home based palliative care are limited, it has even
been suggested that modern day sanatoriumsmay provide access
to palliative care on a large scale, while potentially reducing
onward transmission.28 However this approach has drawn
criticism in equal measure, in part because the impact of
reducing onward transmission by that stage is likely to be small,
and because of potential risks from worsening stigma.29
What are the public health implications?
In addition to the complexities of individual case management,
there are major public health implications to multidrug resistant
tuberculosis. Most transmission is likely to occur before
treatment and hence earlier diagnosis is a key determinant in
the control of multidrug resistant tuberculosis. There is unlikely
to be sufficient bed capacity for full scale-up of hospital based
treatment for multidrug resistant tuberculosis and there is
increasing evidence for ambulatory, community based treatment
that may also reduce the risk of transmission within healthcare
settings. Where inpatient admission is required, triage systems,
strict infection control practices, building design for improved
ventilation (including natural ventilation), and upper room (away
from patients and staff) germicidal ultraviolet light all have an
important role in reducing transmission. Moreover, in other key
transmission hotspots (for example, prisons) there is a need for
active intervention to identify cases and reduce transmission.7
What are the future directions?
Until relatively recently few national, international, or
non-governmental organisations had prioritised multidrug
resistant tuberculosis, with a focus instead on drug susceptible
tuberculosis.6Nowmultidrug resistant tuberculosis forms a key
part in the STOP TB Global Plan to Stop TB 2011-1530 and has
garnered attention at the highest international levels with a
World Health Assembly resolution (WHA 62.15) calling on
WHOmembers to provide universal access tomultidrug resistant
tuberculosis treatment. The STOP TB target is for all patients
with newly diagnosed tuberculosis at high risk for multidrug
resistance and all previously treated patients to undergo drug
susceptibility testing.30 Achieving global control of multidrug
resistant tuberculosis requires timely identification of cases,
enrolment into quality assured treatment with relatively short,
inexpensive, non-toxic treatment, minimisation of transmission,
and accurate epidemiological surveillance. Unfortunately, there
are major challenges to achieving each of these steps.
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Additional educational resources
Resources for healthcare professionals
World Health Organization. Multidrug resistant tuberculosis website (www.who.int/tb/challenges/mdr/en/)—Contains several resources,
including clinical and programmatic guidelines
Lancet Infectious DiseasesMarch-June 2013—Series of papers covering key areas in tuberculosis, with particular relevance for multidrug
resistant tuberculosis
Resources for patients
Centres for Disease Control. Tuberculosis fact sheet (www.cdc.gov/tb/publications/factsheets/drtb/mdrtb.htm)—Provides information
on multidrug resistant tuberculosis
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Table
Table 1| Incidence of tuberculosis and multidrug resistant tuberculosis in selected countries in 2013
% (95% CI) of cases with multidrug resistant tuberculosisNo of new casesSelected countries
RetreatmentNewly diagnosedMultidrug resistant
tuberculosis
Tuberculosis
High burden,* high resistance:†
49 (40 to 59)19 (14 to 25)41 000130 000Russian Federation
26 (22 to 30)5.7 (4.5 to 7)54 2000980 000China
15 (11 to 19)2.2 (1.9 to 2.6)61 0002 100 000India
6.7 (5.4 to 8.2)1.8 (1.4 to 2.3)6800450 000South Africa
Non-high burden, high resistance:†
55 (52 to 57)35 (33 to 37)179065 000Belarus
32 (31 to 33)14 (14 to 15)940044 000Ukraine
Non-high burden, non-high resistance:
35 (33 to 37)3.9 (3.6 to 4.2)205038 000Peru
5.7 (3.2 to 9.4)1.4 (1 to 1.7)698300United Kingdom
3.9 (1.9 to 7.1)1.2 (0.98 to 1.6)10811 000United States
*22 Countries with highest number of cases of tuberculosis.
†27 Countries with highest number of cases of multidrug resistant tuberculosis.
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